Affiliation:
1. School of Social Policy, Sociology & Social Research, Cornwallis North East, University of Kent, Canterbury, Kent CT2 7NF, UK
Abstract
Despite China's regulatory initiatives to promote its research accountability, it still needs to prove itself as a trusted player in life science research. In addition, in contrast to its huge investment, China is losing the race in delivering quality application of stem cells. The trial implementation of the 2015 ministerial regulations seemed to offer hope in ending this dual ‘lost-in-translation’. Yet skepticism remains. By examining China's regulatory trajectory in the last 15 years, this paper illustrates that it is a post hoc pragmatic policy rationale and a soft centralization regulatory approach that have hampered China's governance. To improve China's governance of accountability, policy-makers need to get beyond an ‘act-in-response’ regulatory ethos and to engage with diverse stakeholders.
Subject
Embryology,Biomedical Engineering
Reference57 articles.
1. People's Daily. Exploring stem cell technology: stem cell therapy when will dream come true? (2015). http://news.xinhuanet.com/tech/2015–02/02/c_127447309.htm.
2. The global landscape of stem cell clinical trials
3. National Health and Family Planning Commission, China's Food and Drug Administration. Management of clinical trial research on stem cells (for trial implementation) (2015). www.sda.gov.cn/WS01/CL0053/127243.html.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献